

Cardiovascular disease and Osteoporosis : A Mendelian randomization study

Zhao Wang^{1,5†} Shuyi Zhang^{2†} Hongyang Gong^{3†} Guoxu Zhao^{4†} Hong Xiao⁵ Shuai Yuan⁶ Wenhao Wu⁷ Pai Xu¹ Yihong Chen⁸ Mei Yang⁹
Chan Kang^{1*}

1 Department of Orthopedic Surgery, Chungnam National University School of Medicine, Daejeon, South Korea

2 Department of Orthopedics, Fuzhou second Hospital, Fuzhou, Fujian, China

3 Department of Physiology, College of Medicine, Chosun University, Gwangju, South Korea

4 School of medical imaging, Mudanjiang Medical College, Heilongjiang Province, China

5 Department of Orthopedic, Southwest Hospital Jiangbei Area (The 958th hospital of Chinese People's Liberation Army), Jianxindong Road, Jiang Bei District, Chongqing 400020, China

6 Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Second Military Medical University (Naval Medical University), Shanghai, China

7 Intervention Center Ward Unit 2, Tangdu Hospital, Air Force Medical University, Xi'an, China

8 Department of Clinical Medicine, Xiamen Medical College, Xiamen, China

9 School of Health Science, Mae Fah Luang University, Thailand

†These authors contributed equally to this work and share first authorship

I. Abstract

Background: Cardiovascular disease (CVD) may have some association with osteoporosis (OP). This Mendelian randomization (MR) investigation aimed to explore the potential causal linkage between CVD and OP.

Methods: Utilizing genome-wide association study data from individuals of European descent, we pinpointed Single Nucleotide Polymorphisms (SNPs) relevant to CVD, including those for coronary heart disease (CHD) with 64,762 cases and 22,233 controls, heart failure (HF) comprising 47,309 cases against 930,014 controls, and stroke with a case-control tally of 3,611 to 18,084, to serve as the instrumental variables. Later, we searched for total body bone mineral density (BMD) statistics which were used as phenotypes for OP (sample size = 56,284). In this paper, the traditional inverse variance weighting (IVW) method, the weighted median estimation method, and the MR-Egger method are used to estimate different results. The MR-Egger intercept test, outlier (Mr-PRESSO) test and Cochran-Q statistic are used to detect potential directional pleiotropy and heterogeneity, while we also draw the scatter plot, funnel plot and forest plot. Additionally, a reverse-direction MR analysis was performed to explore the potential for reverse causation.

Results: The IVW analysis showed that CHD could significantly impact total body BMD levels, and every higher standard deviation in the risk of CHD decreased the average total body BMD by 0.0459 units in the IVW analysis (Beta = -0.0459 ; 95%CI = -0.0815 —0.0104, P = 0.0113). Reverse MR analysis showed no significant correlation of the change of total body BMD on the prevalence effect of CHD. No particular relationship exists between HF and total body BMD. There was no significant effect between the changes in total body BMD induced by stroke. Reverse MR analysis revealed no significant correlation between alterations in total body BMD on stroke.

Conclusion: Our analysis points to a substantial causative link between CHD and the vulnerability to OP, potentially paving the way for innovative approaches in treating and preventing OP.

II. Introduction

1. Cardiovascular diseases

Within the landscape of global disease burden, the impact of cardiovascular disease (CVD) is becoming increasingly prominent, not only due to its direct threat to human health but also because of their profound socio-economic repercussions. CVD is the leading cause of death worldwide, with nearly 20 million people succumbing to it in 2017, a figure that far exceeds the global toll of COVID-19¹. Accompanying demographic shifts toward an aging population and changes in lifestyle, the prevalence of CVD is on the rise, presenting unprecedented challenges for individuals, families, and society at large.

2. Osteoporosis

Osteoporosis (OP) is a chronic metabolic bone disease characterized by reduced bone mass, microarchitectural deterioration of bone tissue, reduced bone tension and strength, and increased risk of fragility fractures². The diagnosis of OP is based on bone mineral density (BMD), usually measured by dual-energy X-ray absorptiometry³. According to World Health Organization guidelines, OP is defined as a BMD value less than 2.5 standard deviations below the mean (T-score) of a young, healthy population matched by sex and ethnicity⁴. The global prevalence of OP is 18.3%, with large differences among different ethnic groups and regions⁵. Among the consequences of OP, fractures are one of the most serious and result in a huge economic burden⁶. Therefore, there is a need to explore potential causal risk factors for OP.

3. CVD and OP

The relationship between CVD and OP has become a hot topic of research in the medical field. However, the exact nature of the relationship is still controversial. Many studies have explored the potential relationship between CVD and BMD or fracture risk, but the results are not consistent.

Many large-scale epidemiological studies have found an association between coronary heart disease (CHD) and OP. For example, Marcovitz PA et al. have shown that low BMD can predict coronary artery disease⁷. For another example, the study of DANIELLE L et al. found that patients with CHD were more likely to have problems in BMD⁸. The study based on the third National Health and Nutrition Examination Survey, and patients at higher risk of CHD also had a generally higher risk of lower BMD. In the research by Tekin and colleagues, it was observed that among female subjects, there was no correlation identified between

reduced BMD and CHD, as assessed by angiographic evaluation in those undergoing coronary angiography⁹. The latest longitudinal cohort analysis from Zhu and colleagues indicates that overall BMD might independently predict the likelihood of stroke incidents, particularly among male subjects¹⁰. However, another study incorporating both prospective research and a meta-analysis has drawn conflicting conclusions¹¹.

4. Mendelian randomization

Epidemiology is the scientific study of the distribution of diseases and health outcomes within specific populations¹². The term "classical epidemiology" is used to denote epidemiologic research that does not involve genetics, as opposed to genetic epidemiology. Randomized controlled trials (RCTs) are often considered the gold standard for testing scientific hypotheses in clinical research. While RCTs are theoretically the optimal method for establishing clear causal relationships between specific exposures and outcomes, they have inherent limitations¹³. RCTs are costly and time-consuming, especially when the outcomes of interest are rare or require long-term follow-up. Additionally, it may not always be feasible to intervene solely on the exposure of interest. Moreover, due to practical or ethical reasons, random allocation for certain exposures may not be possible. Observational studies are more readily conducted and often test scientific hypotheses by comparing outcome distributions at varying levels of exposure without intervention. However, differences in outcome distributions between two cohorts can sometimes be incorrectly interpreted as causal effects of exposure. Such conclusions may confound correlation with causation.

Mendelian randomization (MR) design can use observational data to conduct causal association studies, providing an effective way for epidemiological causal inference¹⁴. In 1986, Katan proposed the concept of MR¹⁵. The fundamental idea is to use genetic variants, such as single nucleotide polymorphisms (SNPs), that are strongly correlated with the exposure as instrumental variables (IVs) for modeling to estimate the causal relationship between exposure and outcome. Mendel's law of inheritance describes the random allocation of parental alleles to offspring, rendering gamete formation akin to a "natural" randomized controlled trial that mitigates confounding from factors like living environment, social influences, and acquired behaviors. This random allocation, completed before birth, ensures the proper causal sequence. Hence, the MR method plays a pivotal role in causal inference in epidemiology.

Currently, the MR method is rapidly advancing, classified into two main types based on data characteristics: single-sample MR and two-sample MR. Single-sample MR requires both exposure and outcome to originate from the same dataset, and its establishment demands significant resources, leading to high costs. To overcome this limitation, the two-sample MR was introduced¹⁶, allowing the exposure and outcome to come from two distinct datasets, and enabling the evaluation of the causal effect of exposure on outcome in two non-overlapping

studies. Two-sample MR analysis utilizes existing Genome-Wide Association Studies (GWAS) summary data. Compared to individual data, summary data is more accessible, without ethical constraints. Publicly available summary data also enhances the utility of bioinformatics, thereby reducing research costs.

GWAS analyzes the correlation between complex traits and millions of molecular markers at whole genome level: specifically, SNPs. By contrasting, it identifies genetic variations influencing these complex traits¹⁷. The rapid advancement of GWAS has made two-sample MR an efficient and economical method to explore the causal relationships between health risk factors and disease outcomes.

Thus, this study uses publicly published GWAS summary data, adopts the two-sample MR framework to investigate the causal relationship between CVD and OP. Additionally, by employing a reverse MR analysis, we further validate the study findings, providing fresh insights for the etiological research of OP.

III. Methods

1. Study overview

In our MR examination, total body BMD was chosen as the focal point of study. To encapsulate CVD, we specifically included the most prevalent conditions: CHD, heart failure (HF), and stroke. For the direct MR analysis, SNPs with a high correlation to CHD, HF, and stroke were employed as the IVs. Conversely, in the indirect MR analysis, SNPs with a significant association to total body BMD were utilized. Figure 1 illustrates the schematic of the research approach.

2. Data Source and Definition

A. GWAS summary statistics for BMD

Data for BMD were obtained from the GWAS database (<https://gwas.mrcieu.ac.uk>) of the Integrated Epidemiology Unit (IEC). We selected BMD (sample size = 56,284). The raw data can be found in the Medina-Gomez C study¹⁸. All races selected from the above data are of European ancestry.

B. GWAS summary statistics for CVD (CHD, HF, Stroke)

We selected the data on BMD also based on the large GWAS database. Data for CHD are

relevant from Schunkert H studies exploring genetic variation in 86,995 Europeans (64,762 cases, 22,233 controls)¹⁹. Data for HF can be found in the Shah S article²⁰ (47309 cases, 930014 controls). Stroke was chosen as a variable, with 3,611 instances and 18,084 control entries. Malik R's study ²¹ is the source for the original dataset.

3. Instrumental Genetic Variables

We established a consistent selection threshold for the IVs to adhere to the first principle of MR. First, $P < 1 \times 10^{-5}$ was selected as inclusion condition to obtain statistically significant association analysis results. Second, we performed a linkage disequilibrium analysis of the SNPs corresponding to each instrumental variable ($r^2 = 0.001$, kb = 10000) to ensure that the SNP was independent. To rigorously assess the secondary and tertiary presuppositions of MR, we mitigated the impact of acknowledged confounders on causal inference. Moreover, SNPs linked to CVD were meticulously excised via a phenotype scanning tool available at [<http://www.phenoscanter.medschl.cam.ac.uk>].

Identified confounders for CVD include factors such as lipids, body mass index (BMI), smoking, alcohol consumption, physical activity, sleep duration, educational level, and hypertension²².

Potential confounders associated with BMD include alcoholism, body mass index(BMI), glucocorticoid overdose, hypogonadism, parathyroidism, hyperthyroidism, gastro-intestinal diseases, hypercalciuria, fasting insulin levels, type 2 diabetes, fasting glucose levels, HDL cholesterol levels, depression, sex hormones, lifestyle factors²³.

After screening, we found and excluded some of these IV about BMI in the sensitivity model, and reanalyzed the MR estimates to obtain a more direct causal association.

For each SNP, the F-statistic was derived employing the formula:

$$F = [R^2_{\text{combined}} / (1 - R^2_{\text{combined}})] * [(N - K - 1) / K]$$

Here, R^2 is determined using the equation:

$$R^2 = [\text{beta. exposure}^2] / [\text{se. exposure}^2 * N + \text{beta. exposure}^2]$$

In the above formula, K = number variants comprising instrument, and N = GWAS sample size, beta. exposure = effect of SNP on exposure, se. exposure = standard error for the SNP's exposure effect. The F statistic evaluates the strength of the tool, and the SNP with $F < 10$ is considered weak and removed²⁴.

4. Quantitative Analysis

We investigated the potential causal influence of CVD (CHD, HF, Stroke) on total body BMD, followed by a reverse MR examination to discern the influence of total body BMD on CVD (CHD, HF, Stroke), thereby constituting a bidirectional MR investigation.

The inverse-variance weighted (IVW) method was employed as the principal approach for our analysis²⁵. The IVW method is an ideal estimate and has a strong ability to detect causality. Two additional MR models were also used the weighted median and the MR-Egger method^{26, 27}. They can tolerate the presence of horizontal pleiotropy but have lower statistical power than IVW. The presence of horizontal pleiotropy was estimated by assessing the MR-Egger regression intercept²⁸. Furthermore, the Cochran's Q test was used to assess the heterogeneity between the SNPs in the IVW estimates ($P > 0.05$ indicates no significant heterogeneity). When there is no heterogeneity, we use a fixed effect model, and if heterogeneity is found, we use a random effect model²⁹. If heterogeneity is detected in the MR-PRESSO test³⁰, then we will remove the outlier variant ($P < 0.05$ in the MR-PRESSO test) and perform the MR analysis again. For sensitivity analyses, we used the leave-one-out test³¹ and, after removal, revisited the MR analysis if any variables influenced the causal effect estimates in order to assess potential violations of these assumptions. The influential SNPs were evaluated from two plots (forest, and scatter). All statistical data analyses were performed using R software, version 4.1.3, using the R package for "TwoSampleMR" and "MR-PRESSO"^{30, 32} and considering for difference with $P < 0.05$. Ethical approvals and informed consents for this study can be found in the respective original publications associated with the utilized public databases.

VI. Results

1. Influence of CVD (CHD, HF, Stroke) on total body BMD:

A Causal Assessment

Confounding genes removed are shown in Table 1, 2, 3. Details used for the SNPs related to CVD (CHD, HF, Stroke) and the SNPs associated with total body BMD are listed in Table 4, 5, 6.

We evaluated the causal effect of CHD, HF and Stroke on total body BMD in the MR analysis (Table 7). CHD can significantly affect the incidence of total body BMD, and every higher standard deviation in the risk of CHD decreased the average total body BMD by 0.0459 units in the IVW analysis (Beta = -0.0459, 95%CI = -0.0815--0.0104, $P = 0.0113$)(Table 7). The weighted median method and the MR-Egger method yielded non-significant results (Table 7). HF and Stroke showed no remarkable influence on total body BMD based on the IVW, the weighted median, the MR-Egger analyses (Table 7).

The estimated effect sizes for exposure (CHD, HF, stroke) and outcome total body BMD are shown in the scatter plot (Figure 2). The forest plot is shown in Figure 3.

Heterogeneity tests revealed a lack of significant variation ($P > 0.05$) as indicated in Table 8. Additionally, the MR-Egger intercept suggested an absence of notable horizontal pleiotropy (intercept $P > 0.05$), detailed in Table 9. To evaluate the robustness of individual SNP effects, sensitivity was assessed using the leave-one-out strategy, depicted in Figure 4.

The presence of horizontal pleiotropy was further investigated using MR-PRESSO. This analysis identified a number of aberrant SNPs within the IVs concerning total body BMD on HF, as shown in Table 10. Upon the exclusion of these outliers, subsequent MR-PRESSO analyses did not detect any outlier influences, as reported in Table 11.

2. Influence of total body BMD on CVD (CHD, HF, Stroke):

A Causal Assessment

Confounding genes removed are shown in Table 12, 13, 14. Details used for the SNPs related to total body BMD and the SNPs associated with CVD (CHD, HF, stroke) are listed in Table 15, 16, 17.

We evaluated the causal effect of total body BMD on CVD (CHD, HF, stroke) in the MR analysis (Table 18). Total body BMD showed no remarkable influence on CHD based on the IVW analyses (Beta = 0.0651; 95%CI = -0.0606–0.1907, $P = 0.3101$). Total body BMD showed no remarkable influence on HF based on the IVW analyses (Beta = -0.0154; 95%CI = -0.0603–0.0295, $P = 0.5014$). Total body BMD showed no remarkable influence on Stroke based on the IVW analyses (Beta = 0.0237; 95% CI -0.0287–0.0762, $P = 0.3754$). The weighted median method and the MR-Egger method also indicated non-significant findings (Table 18).

Scatter plot representations of the estimated effect sizes between total body BMD and CVD (CHD, HF, Stroke) are depicted in Figure 5, with a corresponding forest plot presented in Figure 6.

Heterogeneity assessments indicated no significant discrepancies ($P > 0.05$), as recorded in Table 8. Likewise, evidence for horizontal pleiotropy was not observed in the MR-Egger intercept results (intercept $P > 0.05$), listed in Table 9.

The influence of individual SNPs was scrutinized using the leave-one-out approach as a part of our sensitivity analysis, the results of which are displayed in Figure 7.

Horizontal pleiotropy was further examined via MR-PRESSO analysis. This analysis identified several atypical SNPs within the IVs for total body BMD's influence on HF, detailed in Table 19. Subsequent to outlier removal, no further MR-PRESSO outlier detections were reported, as evidenced in Table 11.

V. Discussion

This study represents the most extensive MR investigation into the link between CVD and the risk of OP. The findings from our MR analysis suggest that individuals with CHD may have an increased risk of developing OP. Additionally, the association persisted following sensitivity testing, with no single instrumental variable substantially altering the result.

While the exact pathways driving the relationship between CHD and OP risk remain to be elucidated, there is an accumulating body of research pointing towards a correlation between the two. Numerous large-scale epidemiological studies have identified an association between CHD and OP.

1. Shared Etiological Influences

The hypothesis posits that the concurrent presence of CHD and OP may arise from shared causal factors, such as hypertension, alcohol consumption, physical inactivity, and smoking, which may simultaneously contribute to both atherosclerosis and bone loss. This might shed light on the partial linkage observed between these two conditions³³. Nevertheless, the link between CHD and OP has been consistently observed in numerous epidemiological studies, even after adjusting for many of these risk factors.

2. Common pathophysiological mechanisms

Approximately 90% of coronary atherosclerosis cases are accompanied by coronary artery calcification. It was previously believed that vascular calcification was simply the deposition of calcium in local vascular areas. However, recent research has indicated that vascular calcification is not merely a passive accumulation of calcium salts. Instead, it involves the transformation of local vascular cells into osteogenic cells, and local vascular tissue assumes characteristics akin to bone tissue. This is a highly regulated and reversible biological process, which bears significant similarities to the process of bone mineralization³⁴. Vascular wall cells, including fibroblasts, endothelial cells, macrophages, and vascular smooth muscle cells — particularly the latter under the influence of inflammatory factors and transforming growth factor beta (TGF- β) — can differentiate into osteogenic cells. These osteogenic cells can then secrete a variety of proteins related to bone formation, such as bone morphogenic protein and osteopontin, which may underlie the association between localized vascular calcification and bone metabolism. Based on this association, some scholars have proposed the concept of the 'bone-vascular axis' and posit that vascular calcification is, in essence, an intravascular, programmed osteogenic process driven by various factors³⁵. The similarities and connections between the bone metabolic process and the vascular calcification process may explain the link between CHD and OP. The current study suggests that the common molecular and biological mechanisms underlying the pathogenesis of CHD and OP, along with the biochemical factors impacting both, may primarily include aspects such as the RANK/RANKL/OPG axis³⁶, the Fibroblast Growth Factor 23/Klotho axis^{37,38},

Tubuloglobulin A^{39,40}, osteopontin⁴¹, and TGF- β ^{42,43}.

3. Shared Genetic Contributors

Genes encoding Matrix Gla Protein have been implicated in the development of both atherosclerosis and OP. Research on mice deficient in the Matrix Gla Protein gene revealed a dual phenotype, characterized by vascular calcifications, reduced bone mineral density (BMD), and an increased incidence of fractures⁴⁴.

4. Causal association

Physical activity has also been postulated to be a mediating factor in the relationship between CHD and reduction in BMD. The presence of CHD could restrict levels of physical activity, which in turn may lead to a decrease in BMD.

This investigation acknowledges a number of constraints. Initially, the outcomes from alternative MR methodologies (MR-Egger, weighted median, and mode-based estimations) did not entirely align with those derived from the inverse-variance weighted (IVW) approach in the singular MR analyses. However, in conditions free from heterogeneity and pleiotropy, the IVW estimates are considered the preferred method. Secondly, for the bi-sample MR assessments, the participant pools for the exposure and outcome investigations should be mutually exclusive. The degree of participant overlap in this research was indeterminate. Yet, employing robust analytical instruments (e.g., an F-statistic significantly exceeding 10) can help reduce bias due to sample overlap⁴⁵. Thirdly, while prior MR research indicated a possible causal link of CHD influencing BMD, divergent findings were noted, and the reasons for such discrepancies are yet to be determined. Fourthly, MR analysis segregated by age, sex, and stature was not possible due to the constraints within the GWAS summary statistics. Fifthly, the MR findings were confined to populations of European descent; thus, their extrapolation to Asian ancestries may not be directly transferable.

The prevalence of CHD and OP rises with age, making them leading causes of death and disability. Traditionally, these two conditions have been viewed as unrelated, with their co-occurrence attributed to independent processes associated with aging. However, recent biological and epidemiological evidence suggests a connection between them that goes beyond age and shared risk factors. Some argue that they may share similar molecular, cellular, and biochemical pathways of disease onset. Delving deeper into the link between CHD and OP, and uncovering their mechanisms, may pave the way for novel strategies in treating and preventing OP. From a clinical perspective, subclinical evaluations of OP can be informed by risk stratification for CHD, aiding in the early identification of high-risk OP candidates. Overall, the relationship between CHD and OP remains contentious. Numerous studies provide both supportive and contrary evidence for this connection, which calls for additional research to definitively determine their relationship and the mechanisms underlying it.

VI. Conclusion

In summary, although previous studies have highlighted various risk factors for OP, including menopause, aging, and hormonal treatments, this article specifically focuses on CHD. However, further research is still required. Recognizing these risk factors is crucial for OP prevention and treatment. Notably, the MR approach is recognized as an effective tool for investigating disease risk factors because it adeptly avoids confounding factors and the bias of reverse causation. The MR approach has identified CHD as a potential risk factor for OP. Further investigation into the underlying mechanisms of this relationship can assist in preventing OP and identifying new therapeutic targets.

VII. Data availability statement

Datasets accessible to the public are located at the following source: the Integrative Epidemiology Unit (IEU) GWAS database, available online at (<https://gwas.mrcieu.ac.uk>).

VIII. Author contributions

The study was conceptualized and designed by CK and HX. ZW, SZ, HG, and GZ were responsible for analyzing the data and drafting the manuscript. Manuscript revisions were undertaken by SY. The collection of data was handled by WW and PX. YC and MY provided the necessary resources. CK led the research team. All authors have made substantial contributions to the work and have given their approval to the final version submitted for publication.

IX. Acknowledgments

We thank all of the investigators for sharing summary-level data on GWAS. We would like to thank Figdraw (<https://www.figdraw.com/>) for the drawing help on Figure 1.

XI. Conflict of interest

This research was funded by the project "Therapeutic Strategy and Instrument Development of the Bone Defect Caused by War Trauma," grant number CX2019LC121.

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;11:1736–88. doi: 10.1016/S0140-6736(18)32203-7.
2. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018;319(24):2521-2531. doi: 10.1001/jama.2018.7498.
3. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. *Am J Obstet Gynecol*. 2006;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.
4. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. *J Intern Med*. 2015;277(6):650-61. doi: 10.1111/joim.12369.
5. Salari N, Ghasemi H, Mohammadi L, et al. Global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. *J Orthop Surg Res*. 2021;16(1):609. doi: 10.1186/s13018-021-02821-8
6. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. *Eur J Rheumatol*. 2017;4(1):46-56. doi: 10.5152/eurjrheum.2016.048.
7. Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, Kleerekoper M, Dickinson CZ. Usefulness of bone mineral density to predict significant coronary artery disease. *Am J Cardiol*. 2005 Oct 15;96(8):1059-63. doi: 10.1016/j.amjcard.2005.06.034.
8. Broussard DL, Magnus JH. Coronary heart disease risk and bone mineral density among U.S. women and men. *J Womens Health (Larchmt)*. 2008 Apr;17(3):479-90. doi: 10.1089/jwh.2007.0593.
9. Tekin GO, Kekilli E, Yagmur J, Uckan A, Yagmur C, Aksoy Y, Turhan H, Yetkin E. Evaluation of cardiovascular risk factors and bone mineral density in post menopausal women undergoing coronary angiography. *Int J Cardiol*. 2008 Dec 17;131(1):66-9. doi: 10.1016/j.ijcard.2007.09.002.
10. Pearce N. Classification of epidemiological study designs. *Int J Epidemiol*. 2012;41(2):393–7. doi: 10.1093/ije/dys049.
11. Bothwell LE, Podolsky SH. The Emergence of the Randomized, Controlled Trial. *N Engl J Med*. 2016;375(6):501–4. doi: 10.1056/NEJMp1604635.
12. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32(1):1-22. doi: 10.1093/ije/dyg070.
13. Katan MB. Commentary: Mendelian Randomization, 18 years on. *Int J Epidemiol*. 2004;33(1):10-1. doi: 10.1093/ije/dyh023.

14. Lawlor DA. Commentary: Two-sample Mendelian randomization: opportunities and challenges. *Int J Epidemiol.* 2016;45(3):908–15. doi: 10.1093/ije/dyw127.
15. Swerdlow DI, Kuchenbaecker KB, Shah S, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol.* 2016;45(5):1600-16. doi: 10.1093/ije/dyw088.
16. Medina-Gomez C, Kemp JP, Trajanoska K, et al. Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. *Am J Hum Genet.* 2018;102(1):88-102. doi: 10.1016/j.ajhg.2017.12.005.
17. Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet.* 2011;43(4):333-8. doi: 10.1161/CIRCGENETICS.111.960443.
18. Shah S, Henry A, Roselli C, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nat Commun.* 2020;11(1):163. doi: 10.1038/s41467-019-13690-5.
19. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018;50(4):524-537. doi: 10.1038/s41588-018-0058-3.
20. Van Oort S, Beulens JWJ, van Ballegooijen AJ, Grobbee DE, Larsson SC. Association of Cardiovascular Risk Factors and Lifestyle Behaviors With Hypertension: A Mendelian Randomization Study. *Hypertension.* 2020;76(6):1971-1979. doi: 10.1161/HYPERTENSIONAHA.120.15761
21. Wang H, Cheng J, Wei D, Wu H, Zhao J. Causal relationships between sex hormone traits, lifestyle factors, and osteoporosis in men: A Mendelian randomization study. *PLoS One.* 2022 Aug 4;17(8):e0271898. doi: 10.1371/journal.pone.0271898.
22. Rosoff DB, Smith GD, Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: a multivariable mendelian randomization analysis. *JAMA Psychiatry.* (2021) 2:151– 60. doi: 10.1001/jamapsychiatry.2020.3554
23. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res.* (2020) 4:186. doi: 10.12688/wellcomeopenres.15555.2
24. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013;37(7):658–65. doi: 10.1002/gepi.21758.
25. Burgess S, Bowden J, Fall T, etc. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. *Epidemiology.* (2017) 1:30–42. doi: 10.1097/EDE.0000000000000559
26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* (2015) 4:512–25. doi: 10.1093/ije/dyv080

27. Bowden J, Del Greco MF, Minelli C, etc. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med.* 2017;36(11):1783–1802. doi: 10.1002/sim.7221.
28. Verbanck M, Chen CY, Neale B, etc. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. *Nat Genet.* (2018)5:693–8. doi: 10.1038/s41588-018-0099-7
29. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations. *Wellcome Open Res.* (2020) 4:186. doi: 10.12688/wellcomeopenres.15555.2
30. Hemani G, Zheng J, Elsworth B, et al. The MR-Base Platform Supports Systematic Causal Inference Across the Human Phenome. *Elife.* (2018) 5:e34408. doi: 10.7554/eLife.34408.012
31. Alagiakrishnan K, Juby A, Hanley D, Tymchak W, Sclater A. Role of vascular factors in osteoporosis. *J Gerontol A Biol Sci Med Sci.* 2003 Apr;58(4):362-6. doi: 10.1093/gerona/58.4.m362.
32. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? *Osteoporos Int.* (2009) 20(2):197-207. doi: 10.1007/s00198-008-0648-5.
33. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. *Nat Rev Endocrinol.* 2012 Sep;8(9):529-43. doi: 10.1038/nrendo.2012.36.
34. Yamamoto M. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification as a clinical manifestation of bone-vascular axis]. *Clin Calcium.* 2015 May;25(5):655-60. PMID: 25926568.
35. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N, Richards WG. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. *Calcif Tissue Int.* 2011 Aug;89(2):140-50. doi: 10.1007/s00223-011-9501-5.
36. Cianciolo G, Galassi A, Capelli I, Schillaci R, La Manna G, Cozzolino M. Klotho-FGF23, Cardiovascular Disease, and Vascular Calcification: Black or White? *Curr Vasc Pharmacol.* 2018 Jan 26;16(2):143-156. doi: 10.2174/1570161115666170310092202.
37. Westenfeld R, Schäfer C, Krüger T, Haarmann C, Schurgers LJ, Reutelingsperger C, Ivanovski O, Druke T, Massy ZA, Ketteler M, Floege J, Jahnke-Dechent W. Fetuin-A protects against atherosclerotic calcification in CKD. *J Am Soc Nephrol.* 2009 Jun;20(6):1264-74. doi: 10.1681/ASN.2008060572.
38. Wu Q, Xiao DM, Fan WF, Ye XW, Niu JY, Gu Y. Effect of serum fibroblast growth factor-23, matrix Gla protein and Fetuin-A in predicting osteoporosis in maintenance hemodialysis patients. *Ther Apher Dial.* 2014 Oct;18(5):427-33. doi: 10.1111/1744-9987.12194.
39. Speer MY, Chien YC, Quan M, Yang HY, Vali H, McKee MD, Giachelli CM. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. *Cardiovasc Res.* 2005 May 1;66(2):324-33. doi: 10.1016/j.cardiores.2005.01.023.
40. Toma I, McCaffrey TA. Transforming growth factor- β and atherosclerosis: interwoven atherogenic and

atheroprotective aspects. *Cell Tissue Res.* 2012 Jan;347(1):155-75. doi: 10.1007/s00441-011-1189-3.

41. Karst M, Gorny G, Galvin RJ, Oursler MJ. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. *J Cell Physiol.* 2004 Jul;200(1):99-106. doi: 10.1002/jcp.20036.

42. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature.* 1997;386:78–81. doi: 10.1038/386078a0.

43. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *Am J Epidemiol.* (2013) 10:1177–84. doi: 10.1093/aje/kwt084

CONTENTS OF TABLES

Table1 The removed SNPs containing known confounding factors of CHD on total body BMD

SNP	Chr	Pos	EA	OA	CHD (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs1333045	9	22119195	C	T	0.226084	0.0058	0.8407	0.0012	0.0058	0.8407
rs7651039	3	15648004	C	T	0.142119	0.0058	0.5386	-0.0036	0.0058	0.5386
rs964184	11	116648917	C	G	-0.12596	0.0082	0.1916	0.0107	0.0082	0.1916

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; CHD, coronary heart disease.

Table2 The removed SNP containing known confounding factors of HF on total body BMD

SNP	Chr	Pos	EA	OA	HF (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs56094641	16	53806453	G	A	0.0454	0.008	1.20801E-08	-0.012	0.0059	0.0401698

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; HF, heart failure.

Table3 The removed SNP containing known confounding factors of stroke on total body BMD

SNP	Chr	Pos	EA	OA	Stroke (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs3184504	12	111884608	C	T	-0.0779	0.0101	1.22914E-14	0.0193	0.0058	0.000845493

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density.

Table 4 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of CHD and risk of total body BMD

SNP	Chr	Pos	EA	OA	CHD (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs10455872	6	161010118	G	A	0.27787	0.038112	3.08035E-13	-0.023	0.0127	0.0711803
rs1122608	19	11163601	T	G	-0.127428	0.0208429	9.72994E-10	0.0004	0.0067	0.9498
rs11556924	7	129663496	T	C	-0.0905122	0.0151329	2.21998E-09	0.0133	0.0062	0.0328897
rs12190287	6	134214525	G	C	-0.103209	0.0156807	4.63981E-11	0.0023	0.0063	0.713199
rs1333045	9	22119195	C	T	0.226084	0.019183	4.6302E-32	0.0012	0.0058	0.8407
rs17114036	1	56962821	G	A	-0.144965	0.0255686	1.43001E-08	0.004	0.0096	0.6773
rs2219939	15	79029723	A	G	-0.0990217	0.016288	1.21001E-09	-0.007	0.007	0.3202
rs2306374	3	138119952	C	T	0.108439	0.019636	3.34003E-08	-0.0161	0.0078	0.0397201
rs2351524	2	203880992	C	T	-0.13869	0.0206229	1.75995E-11	-0.0009	0.0088	0.9145
rs4714955	6	12903435	T	C	-0.0997862	0.0145058	6.02976E-12	0.0006	0.0063	0.9245
rs599839	1	109822166	A	G	0.106715	0.0169259	2.89001E-10	-0.0142	0.0067	0.0337598
rs7651039	3	15648004	C	T	0.142119	0.0252631	1.84999E-08	-0.0036	0.0058	0.5386
rs9351814	6	72193707	C	A	-0.0795946	0.0141883	2.01999E-08	0.0005	0.0058	0.9358
rs964184	11	116648917	C	G	-0.12596	0.0204991	8.01992E-10	0.0107	0.0082	0.1916
rs9982601	21	35599128	T	C	0.163991	0.0262564	4.21998E-10	-0.007	0.0085	0.4115

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; CHD, coronary heart disease.

Table 5 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of HF and risk of total body BMD

SNP	Chr	Pos	EA	OA	HF (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs11745324	5	137012171	A	G	-0.0528	0.0095	2.34498E-08	0.0064	0.0069	0.3533
rs1510226	6	160816409	C	T	0.162	0.0285	1.26599E-08	0.0079	0.0211	0.709999
rs1556516	9	22100176	C	G	0.0622	0.0078	1.56892E-15	0.001	0.0057	0.8585
rs17042102	4	111668626	A	G	0.1103	0.0121	5.70558E-20	-0.0056	0.009	0.530401
rs17617337	10	121426884	T	C	-0.0561	0.0095	3.65401E-09	-0.0019	0.007	0.789
rs4746140	10	75417249	C	G	-0.0666	0.0109	1.104E-09	0.006	0.0076	0.4308
rs55730499	6	161005610	T	C	0.1058	0.0157	1.83021E-11	-0.0212	0.0126	0.0933405

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; HF, heart failure.

Table 6 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of stroke and risk of total body BMD

SNP	Chr	Pos	EA	OA	Stroke (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs11242678	6	1337180	T	C	0.0723	0.0114	2.70302E-10	-0.0051	0.0065	0.4342
rs2066864	4	155525695	A	G	0.0634	0.0115	3.51399E-08	-0.0032	0.0065	0.622801
rs2107595	7	19049388	A	G	0.0882	0.0132	2.32809E-11	0.0009	0.0076	0.904
rs2634074	4	111677041	A	T	-0.0941	0.0121	5.90473E-15	0.0047	0.0069	0.496
rs2758612	1	156205301	C	T	-0.0653	0.0111	3.67697E-09	0.0011	0.0061	0.8623
rs34311906	4	113732090	C	T	0.0649	0.0113	1.06601E-08	-0.0002	0.0063	0.9722
rs473238	11	102700360	C	T	-0.0831	0.0147	1.65101E-08	0.0102	0.0084	0.2249
rs4942561	13	47209347	T	G	0.0655	0.0116	1.77101E-08	0.0169	0.0066	0.01065

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density.

Table 7 Mendelian Randomization estimates of CHD, HF and Stroke on total body BMD

Exposure	Outcome	IV				Weighted median			MR-Egger			F-statistic
		SNPs(N)	Beta	95% CI	P-value	Beta	95% CI	P-value	Beta	95% CI	P-value	
CHD	Total body BMD	12	-0.045	-0.0815–0.0	0.0113	-0.02	-0.0752–0.	0.287	-0.066	-0.1913–0.	0.3213	39.5245
		9		104		64	0223	7	4	0584		
HF	Total body BMD	5	-0.059	-0.1568–0.0	0.2354	-0.05	-0.1764–0.	0.426	-0.051	-0.3134–0.	0.7261	46.7991
		1		386		10	0745	0	4	2105		
Stroke	Total body BMD	8	-0.010	-0.0838–0.06	0.7725	-0.03	-0.1173–0.0	0.387	-0.238	-0.7306–0.	0.3797	38.4196
		8		22		59	455	7	2	2542		

Abbreviations: BMD, bone mineral density; CHD, coronary heart disease; HF, heart failure; IVW, inverse-variance weighted; CI, confidence interval; MR Mendelian randomization; IV:instrumental variable

Table 8 Results of heterogeneity analysis

Exposure	Outcome	Q-value (IVW)	Heterogeneity
			P-value (IVW)
CHD		11.7756	0.3807
HF	Total body BMD	2.8845	0.5773
Stroke		9.2898	0.2325
	CHD	47.4325	0.0500
Total body BMD	HF	81.9906	0.1028
	Stroke	92.2252	0.1466

Abbreviations: BMD, bone mineral density; CHD, coronary heart disease; HF, heart failure; IVW, inverse-variance weighted;

Table9 Results of MR-Egger intercept test

Exposure	Outcome	Egger intercept	P-value	Se
CHD		0.0025	0.7429	0.0076
HF	Total body BMD	-0.0007	0.9542	0.0107
Stroke		0.0170	0.3952	0.0186
	CHD	-0.0057	0.4995	0.0084
Total body BMD	HF	0.0014	0.6758	0.0033
	Stroke	-0.0029	0.4616	0.0039

Abbreviations: BMD, bone mineral density; CHD, coronary heart disease; HF, heart failure; Se, standard error

Table 10 Abnormal SNPs in MR-PRESSO analysis of HF on total body BMD

SNP	Chr	Pos	EA	OA	HF (Exposure)			Total body BMD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs4135240	6	36647680	C	T	-0.0486	0.0084	6.83801E-09	-0.0117	0.0061	0.0525702
rs4766578	12	111904371	A	T	-0.0433	0.0079	4.89903E-08	0.0201	0.0058	0.000579002
rs660240	1	109817838	C	T	0.0611	0.0097	3.25102E-10	-0.0225	0.0068	0.000986007

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; HF, heart failure; BMD, bone mineral density.

Table 11 MR-PRESSO test of all the results

Exposure	Outcomes	Global p-value	Number of outliers	Distortion p-value
CHD		0.394	0	NA
HF	Total body BMD	0.073	0	NA
Stroke		0.223	0	NA
	CHD	0.412	0	NA
Total body BMD	HF	0.088	0	NA
	Stroke	0.2	0	NA

Abbreviations: SNP, single-nucleotide polymorphism; BMD, bone mineral density; CHD, coronary heart disease; HF, heart failure; MR-PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier

Table12 The removed SNP containing known confounding factors of total body BMD on CHD

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			CHD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs13204965	6	127167072	C	A	-0.0619	0.007	1.01508E-18	0.0137275	0.0170065	0.419557

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; CHD, coronary heart disease.

Table13 The removed SNP containing known confounding factors of total body BMD on HF

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			HF (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs13204965	6	127167072	C	A	-0.0619	0.007	1.01508E-18	-0.0011	0.0092	0.9065
rs780096	2	27741072	G	C	0.0311	0.0057	4.57699E-08	-0.0079	0.0079	0.3157

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; HF, heart failure.

Table14 The removed SNP containing known confounding factors of total body BMD on stroke

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			Stroke (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs13204965	6	127167072	C	A	-0.0619	0.007	1.01508E-18	-0.0286	0.012	0.01741
rs780096	2	27741072	G	C	0.0311	0.0057	4.57699E-08	-0.0113	0.0107	0.2926

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density.

Table 15 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of total body BMD and risk of CHD

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			CHD (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs10490046	2	40630678	C	A	-0.0429	0.0067	1.434E-10	-0.0250067	0.0189856	0.187791
rs10493013	1	22703035	C	T	0.1013	0.0074	4.07474E-43	-0.0033062	0.0180114	0.854356
rs10777212	12	90334829	T	G	0.0452	0.006	5.05126E-14	0.0155206	0.0149326	0.29863
rs10788264	10	124015986	A	G	-0.0338	0.0057	2.60597E-09	0.0298681	0.0144376	0.0385665
rs10832520	11	15816918	A	T	0.1123	0.0158	1.00092E-12	0.0003941	0.0406626	0.992266
rs11745493	5	122847622	G	A	-0.0445	0.0065	7.74462E-12	-0.0157347	0.0159937	0.32521
rs11898505	2	54684557	G	A	-0.0342	0.006	1.28201E-08	0.01481	0.0173628	0.393672
rs11904127	2	85484818	A	G	-0.0324	0.0057	1.18201E-08	0.0147723	0.0142359	0.299419
rs11910328	21	40350744	A	G	-0.0429	0.0077	2.99302E-08	-0.0157575	0.0209145	0.451196
rs11995824	8	120012700	G	C	-0.0675	0.0058	1.06194E-31	0.009329	0.014028	0.506032
rs1286150	14	91464890	C	T	0.0549	0.0072	2.44174E-14	0.0166644	0.0205679	0.417816
rs1452102	21	28773868	G	T	0.0345	0.0057	1.736E-09	0.0147094	0.0141731	0.299344
rs1548607	7	50901491	G	A	-0.0363	0.0066	4.18398E-08	-0.00224	0.0241312	0.926041
rs2252865	1	8422676	C	T	0.0328	0.006	4.71998E-08	-0.00592	0.0156861	0.705877

rs2289410	2	42284110	T	A	-0.0494	0.0088	2.00198E-08	-0.01071	0.0203295	0.598319
rs2350085	2	202799604	C	T	0.0643	0.0085	3.7949E-14	-0.0028758	0.0258901	0.911555
rs2553773	11	35083633	G	C	0.037	0.0058	1.493E-10	-0.0050188	0.0140362	0.720671
rs3743347	15	67547301	A	C	0.0519	0.0068	1.75186E-14	0.0026659	0.0166768	0.872992
rs3801387	7	120974765	G	A	0.1347	0.0063	1.15001E-100	0.0058124	0.0164557	0.723929
rs4757350	11	15703674	T	C	-0.0564	0.0069	3.75405E-16	-0.0332794	0.017658	0.0594758
rs4846580	1	219897941	A	G	0.0345	0.0058	3.21299E-09	0.0011301	0.0140137	0.935728
rs633995	1	172186729	A	G	0.0351	0.0058	1.61298E-09	-0.0268112	0.0152785	0.0792885
rs634277	11	86887931	G	A	-0.0607	0.0061	2.15179E-23	0.0061239	0.0150167	0.683419
rs6465511	7	96134115	G	C	0.0738	0.006	1.02802E-34	0.0428886	0.0151026	0.00451398
rs6960249	7	96660132	G	T	-0.0325	0.0057	1.44901E-08	0.0008693	0.0139862	0.95044
rs725670	11	121913230	A	G	-0.0322	0.0059	3.61202E-08	-0.0105581	0.0150037	0.481621
rs7586085	2	166577489	G	A	-0.0532	0.0057	8.63575E-21	0.0080914	0.013737	0.555849
rs7740042	6	151971720	A	T	-0.0494	0.0071	2.70707E-12	-0.0007803	0.0180184	0.965456
rs7741085	6	44636919	T	C	0.0423	0.0057	1.50904E-13	-0.0203963	0.0144119	0.156997
rs8070128	17	17804725	T	C	-0.0394	0.0059	1.98381E-11	-0.0602312	0.0152666	7.97003E-05

rs818427	5	112221869	T	C	0.0342	0.0061	2.37197E-08	-0.0096668	0.0147448	0.512079
rs884205	18	60054857	C	A	0.0531	0.0068	4.39036E-15	-0.0069028	0.0209862	0.742215
rs9594738	13	42952145	T	C	-0.0614	0.0057	3.84061E-27	-0.0026926	0.0138033	0.845337
rs9910055	17	42283037	T	C	0.0442	0.0067	3.11889E-11	-0.0244568	0.0168909	0.147638
rs9972944	17	63771079	G	A	-0.0363	0.0059	6.86594E-10	-0.0024013	0.0143354	0.866968
rs9976876	21	36970350	T	G	-0.0375	0.0058	8.00571E-11	0.0051571	0.014061	0.713793

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; CHD, coronary heart disease.

Table 16 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of total body BM D and risk of HF

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			HF (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs10048745	2	68962137	A	G	-0.0389	0.0067	6.44006E-09	-0.0035	0.0092	0.7077
rs1037011	12	107302778	C	T	0.0404	0.0057	1.54099E-12	-0.0234	0.0078	0.00285397
rs10490046	2	40630678	C	A	-0.0429	0.0067	1.434E-10	-0.0093	0.0094	0.3206
rs10493013	1	22703035	C	T	0.1013	0.0074	4.07474E-43	-0.002	0.0104	0.8496
rs10735851	12	53743064	A	G	-0.0541	0.0063	5.84252E-18	-0.0175	0.0087	0.0439805
rs10777212	12	90334829	T	G	0.0452	0.006	5.05126E-14	0.0025	0.0083	0.765799
rs10788264	10	124015986	A	G	-0.0338	0.0057	2.60597E-09	0.0122	0.0079	0.123
rs10832520	11	15816918	A	T	0.1123	0.0158	1.00092E-12	-0.0316	0.0231	0.1715
rs10901216	9	133471891	A	G	-0.0474	0.0061	5.5335E-15	-0.0056	0.0082	0.4942
rs10931982	2	202832130	C	T	0.0508	0.009	1.585E-08	-0.0049	0.0108	0.649101
rs11228240	11	68218290	T	C	-0.083	0.0067	1.71791E-35	-0.0026	0.0089	0.7724
rs1159798	10	54412493	C	A	-0.0429	0.007	1.014E-09	0.0142	0.0098	0.148
rs11745493	5	122847622	G	A	-0.0445	0.0065	7.74462E-12	-0.0112	0.0091	0.2191
rs117557198	12	49655948	G	A	0.0769	0.012	1.575E-10	0.0084	0.0153	0.585301
rs11898505	2	54684557	G	A	-0.0342	0.006	1.28201E-08	0.0038	0.0084	0.649299
rs11904127	2	85484818	A	G	-0.0324	0.0057	1.18201E-08	-0.0008	0.0079	0.9226
rs11910328	21	40350744	A	G	-0.0429	0.0077	2.99302E-08	0.0133	0.0106	0.2119
rs11934731	4	88831249	A	G	-0.0674	0.0061	8.38687E-29	0.0038	0.0084	0.651199
rs11995824	8	120012700	G	C	-0.0675	0.0058	1.06194E-31	-0.0033	0.0079	0.681
rs12044944	1	240581653	T	C	0.0553	0.0074	7.54223E-14	-0.0002	0.01	0.9816
rs12258451	10	54423853	G	C	-0.0702	0.0089	2.41213E-15	-0.0041	0.0124	0.7431
rs12442242	15	38340874	G	A	0.0509	0.0082	4.94106E-10	0.0234	0.0118	0.0469699
rs12534510	7	120730944	C	A	0.0395	0.0057	3.14775E-12	0.01	0.0079	0.2059

rs12612325	2	119632252	A	G	-0.0548	0.0078	1.98198E-12	-0.0062	0.0105	0.5562
rs1286150	14	91464890	C	T	0.0549	0.0072	2.44174E-14	-0.0125	0.0103	0.2271
rs143187557	11	47284279	T	C	-0.1237	0.0203	1.15401E-09	-0.0106	0.028	0.704601
rs144279715	2	119548256	G	A	0.2295	0.0294	6.18443E-15	-0.0275	0.0323	0.3947
rs144691710	17	41819562	G	A	0.1017	0.0113	2.23924E-19	0.0021	0.0145	0.8827
rs1452102	21	28773868	G	T	0.0345	0.0057	1.736E-09	-0.0039	0.0079	0.621199
rs1548607	7	50901491	G	A	-0.0363	0.0066	4.18398E-08	0.0044	0.0087	0.614301
rs2252865	1	8422676	C	T	0.0328	0.006	4.71998E-08	0.0054	0.0083	0.5161
rs2289410	2	42284110	T	A	-0.0494	0.0088	2.00198E-08	-0.0001	0.0121	0.9917
rs2350085	2	202799604	C	T	0.0643	0.0085	3.7949E-14	-0.0056	0.012	0.6389
rs2414098	15	51537806	C	T	0.0329	0.0059	1.98701E-08	-0.007	0.0119	0.554
rs2553773	11	35083633	G	C	0.037	0.0058	1.493E-10	0.0119	0.0079	0.1288
rs2566751	1	68664913	A	T	-0.0567	0.01	1.31899E-08	-0.024	0.0138	0.0815098
rs2566752	1	68656697	C	T	0.0721	0.0059	1.87715E-34	-0.0045	0.0081	0.5819
rs34102936	7	38142840	A	G	0.0471	0.0057	1.86595E-16	-0.0052	0.008	0.5181
rs34670419	7	99130834	T	G	-0.088	0.0154	1.087E-08	-0.0551	0.0192	0.00421202
rs35125553	12	1639249	G	A	0.0383	0.0066	5.202E-09	-0.0038	0.0089	0.666099
rs35199438	11	16630779	T	G	-0.0489	0.0062	2.35993E-15	0.0035	0.0084	0.6758
rs3743347	15	67547301	A	C	0.0519	0.0068	1.75186E-14	-0.0208	0.0094	0.0260399
rs3801387	7	120974765	G	A	0.1347	0.0063	1.15001E-100	-0.0043	0.0089	0.6321
rs447911	3	41127046	C	G	0.0708	0.0057	6.29361E-36	0.0002	0.0079	0.9813
rs4757350	11	15703674	T	C	-0.0564	0.0069	3.75405E-16	0.0106	0.0097	0.2714
rs4846580	1	219897941	A	G	0.0345	0.0058	3.21299E-09	0.0065	0.0079	0.4136
rs55781332	11	242859	G	A	0.0552	0.0069	8.07235E-16	-0.0087	0.0093	0.349
rs56104760	1	22486029	G	A	-0.0747	0.0074	7.37734E-24	0.0131	0.0098	0.1801
rs6029130	20	39103882	T	C	0.0348	0.0063	3.503E-08	-0.0055	0.0089	0.5353

rs6040063	20	10640877	G	A	-0.0359	0.0056	1.78098E-10	-0.0106	0.0078	0.175
rs61884327	11	46766890	C	T	0.0801	0.0099	4.63447E-16	0.0143	0.0133	0.2806
rs633995	1	172186729	A	G	0.0351	0.0058	1.61298E-09	-0.0043	0.0081	0.5961
rs634277	11	86887931	G	A	-0.0607	0.0061	2.15179E-23	0.0052	0.0084	0.5389
rs6465511	7	96134115	G	C	0.0738	0.006	1.02802E-34	0.0004	0.0082	0.9618
rs6557155	6	151910126	G	T	0.0751	0.0059	2.55918E-37	-0.0157	0.0081	0.0524699
rs6960249	7	96660132	G	T	-0.0325	0.0057	1.44901E-08	-0.006	0.0079	0.4486
rs7105860	11	27306364	C	G	-0.0468	0.0059	2.35885E-15	0.0011	0.0081	0.8958
rs71390846	16	86714715	C	G	-0.0484	0.0075	1.38099E-10	0.0084	0.0101	0.4032
rs725670	11	121913230	A	G	-0.0322	0.0059	3.61202E-08	-0.0027	0.0081	0.7392
rs73169678	7	150953205	A	C	0.0619	0.0091	1.05293E-11	-0.0191	0.0122	0.1172
rs73305797	7	30997087	T	A	-0.0422	0.0067	2.398E-10	0.01	0.0092	0.2759
rs73719807	7	121191251	C	A	0.0925	0.0112	1.14288E-16	-0.0252	0.0165	0.1263
rs74394007	3	156692207	C	A	-0.0608	0.0083	2.46093E-13	-0.0004	0.0115	0.9742
rs7548588	1	110475971	C	T	0.0367	0.0058	2.208E-10	-0.0104	0.0079	0.1887
rs757138	7	27989403	G	T	0.0348	0.0063	3.33403E-08	0.0048	0.0088	0.5875
rs7586085	2	166577489	G	A	-0.0532	0.0057	8.63575E-21	-0.0004	0.0079	0.956
rs76051363	4	1006987	T	C	-0.0794	0.0085	1.38995E-20	-0.0045	0.0113	0.691
rs7728694	5	88288341	T	G	-0.0503	0.0059	1.29599E-17	-0.0125	0.008	0.1155
rs7740042	6	151971720	A	T	-0.0494	0.0071	2.70707E-12	0.0211	0.0098	0.03125
rs7741085	6	44636919	T	C	0.0423	0.0057	1.50904E-13	0.0008	0.0079	0.9218
rs78667121	13	43200103	A	G	0.1326	0.018	1.70098E-13	0.008	0.0231	0.728201
rs8047501	16	392318	G	A	-0.0524	0.0059	1.13397E-18	0.0044	0.0081	0.5894
rs8070128	17	17804725	T	C	-0.0394	0.0059	1.98381E-11	-0.0223	0.008	0.00541203
rs818427	5	112221869	T	C	0.0342	0.0061	2.37197E-08	0.0064	0.0082	0.4359
rs838721	2	234303405	G	A	0.0314	0.0057	4.48002E-08	-0.0118	0.0079	0.1326

rs884205	18	60054857	C	A	0.0531	0.0068	4.39036E-15	0.0063	0.0091	0.489199
rs9594738	13	42952145	T	C	-0.0614	0.0057	3.84061E-27	-0.0059	0.0079	0.4566
rs9910055	17	42283037	T	C	0.0442	0.0067	3.11889E-11	0.004	0.0093	0.6693
rs9972944	17	63771079	G	A	-0.0363	0.0059	6.86594E-10	0.0018	0.0118	0.881
rs9976876	21	36970350	T	G	-0.0375	0.0058	8.00571E-11	-0.0042	0.0079	0.5894

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density; HF, heart failure.

Table 17 Association of the SNPs used as candidate genetic instruments from the GWAS for Mendelian randomization analyses of total body BMD and risk of stroke

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			Stroke (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs10048745	2	68962137	A	G	-0.0389	0.0067	6.44006E-09	-0.0087	0.0129	0.501601
rs1037011	12	107302778	C	T	0.0404	0.0057	1.54099E-12	0.0019	0.0099	0.8492
rs10490046	2	40630678	C	A	-0.0429	0.0067	1.434E-10	0.0022	0.0126	0.8586
rs10493013	1	22703035	C	T	0.1013	0.0074	4.07474E-43	-0.0177	0.0131	0.1759
rs10735851	12	53743064	A	G	-0.0541	0.0063	5.84252E-18	-0.0017	0.0103	0.8706
rs10777212	12	90334829	T	G	0.0452	0.006	5.05126E-14	-0.0066	0.0105	0.5308
rs10788264	10	124015986	A	G	-0.0338	0.0057	2.60597E-09	0.009	0.0099	0.3609
rs10832520	11	15816918	A	T	0.1123	0.0158	1.00092E-12	0.031	0.0294	0.2922
rs10901216	9	133471891	A	G	-0.0474	0.0061	5.5335E-15	-0.0013	0.0105	0.8999
rs10931982	2	202832130	C	T	0.0508	0.009	1.585E-08	0.026	0.0153	0.0886605
rs11228240	11	68218290	T	C	-0.083	0.0067	1.71791E-35	-0.0205	0.0118	0.0834392
rs1159798	10	54412493	C	A	-0.0429	0.007	1.014E-09	-0.0008	0.0125	0.9519
rs11745493	5	122847622	G	A	-0.0445	0.0065	7.74462E-12	0.0159	0.0112	0.1586
rs117557198	12	49655948	G	A	0.0769	0.012	1.575E-10	0.009	0.02	0.6543
rs118115924	12	49379537	T	G	-0.2822	0.0301	6.98554E-21	0.0487	0.0598	0.4154
rs11898505	2	54684557	G	A	-0.0342	0.006	1.28201E-08	0.0313	0.0107	0.00360296
rs11904127	2	85484818	A	G	-0.0324	0.0057	1.18201E-08	-0.0197	0.0101	0.0498196
rs11910328	21	40350744	A	G	-0.0429	0.0077	2.99302E-08	-0.0014	0.0135	0.9151
rs11934731	4	88831249	A	G	-0.0674	0.0061	8.38687E-29	0.0181	0.0106	0.0888198
rs11995824	8	120012700	G	C	-0.0675	0.0058	1.06194E-31	0.0021	0.0102	0.8398
rs12044944	1	240581653	T	C	0.0553	0.0074	7.54223E-14	-0.0061	0.0129	0.637699
rs12258451	10	54423853	G	C	-0.0702	0.0089	2.41213E-15	-0.0058	0.0163	0.723199
rs12442242	15	38340874	G	A	0.0509	0.0082	4.94106E-10	0.0082	0.0147	0.5779

rs12534510	7	120730944	C	A	0.0395	0.0057	3.14775E-12	0.0058	0.0099	0.5595
rs12612325	2	119632252	A	G	-0.0548	0.0078	1.98198E-12	-0.005	0.0142	0.7248
rs1286150	14	91464890	C	T	0.0549	0.0072	2.44174E-14	-0.0079	0.0131	0.5474
rs143187557	11	47284279	T	C	-0.1237	0.0203	1.15401E-09	-0.0561	0.0374	0.1336
rs144279715	2	119548256	G	A	0.2295	0.0294	6.18443E-15	0.0161	0.0508	0.7516
rs144691710	17	41819562	G	A	0.1017	0.0113	2.23924E-19	0.0065	0.0197	0.7431
rs1452102	21	28773868	G	T	0.0345	0.0057	1.736E-09	-0.0033	0.0103	0.7461
rs1548607	7	50901491	G	A	-0.0363	0.0066	4.18398E-08	0.0012	0.0114	0.9181
rs2252865	1	8422676	C	T	0.0328	0.006	4.71998E-08	-0.0171	0.0104	0.099211
rs2289410	2	42284110	T	A	-0.0494	0.0088	2.00198E-08	0.0267	0.0162	0.0994008
rs2350085	2	202799604	C	T	0.0643	0.0085	3.7949E-14	0.0144	0.0152	0.3436
rs2414098	15	51537806	C	T	0.0329	0.0059	1.98701E-08	0.0205	0.0106	0.0538096
rs2553773	11	35083633	G	C	0.037	0.0058	1.493E-10	0.0034	0.01	0.734999
rs2566751	1	68664913	A	T	-0.0567	0.01	1.31899E-08	0.0178	0.0182	0.3278
rs2566752	1	68656697	C	T	0.0721	0.0059	1.87715E-34	-0.0081	0.0102	0.4277
rs2873195	17	2064702	T	A	0.0406	0.0062	4.31122E-11	0.021	0.0112	0.0601395
rs34102936	7	38142840	A	G	0.0471	0.0057	1.86595E-16	0.0042	0.0098	0.668199
rs34670419	7	99130834	T	G	-0.088	0.0154	1.087E-08	-0.0362	0.0258	0.1606
rs35125553	12	1639249	G	A	0.0383	0.0066	5.202E-09	0.0157	0.0115	0.172
rs35199438	11	16630779	T	G	-0.0489	0.0062	2.35993E-15	0.0061	0.0106	0.569
rs3743347	15	67547301	A	C	0.0519	0.0068	1.75186E-14	-0.0103	0.012	0.3926
rs3801387	7	120974765	G	A	0.1347	0.0063	1.15001E-100	0.0085	0.0111	0.4434
rs447911	3	41127046	C	G	0.0708	0.0057	6.29361E-36	0.0039	0.0101	0.7014
rs4757350	11	15703674	T	C	-0.0564	0.0069	3.75405E-16	-0.016	0.014	0.2511
rs4846580	1	219897941	A	G	0.0345	0.0058	3.21299E-09	-0.0077	0.0101	0.4448
rs55781332	11	242859	G	A	0.0552	0.0069	8.07235E-16	-0.0022	0.0119	0.8551

rs56104760	1	22486029	G	A	-0.0747	0.0074	7.37734E-24	-0.0048	0.0128	0.709099
rs6029130	20	39103882	T	C	0.0348	0.0063	3.503E-08	0.0181	0.0115	0.115
rs6040063	20	10640877	G	A	-0.0359	0.0056	1.78098E-10	0.002	0.0099	0.8378
rs61884327	11	46766890	C	T	0.0801	0.0099	4.63447E-16	0.0334	0.0171	0.0509096
rs633995	1	172186729	A	G	0.0351	0.0058	1.61298E-09	-0.0105	0.01	0.294
rs634277	11	86887931	G	A	-0.0607	0.0061	2.15179E-23	-0.011	0.0107	0.3026
rs6465511	7	96134115	G	C	0.0738	0.006	1.02802E-34	0.016	0.0107	0.1363
rs6557155	6	151910126	G	T	0.0751	0.0059	2.55918E-37	-0.0141	0.0104	0.1756
rs6960249	7	96660132	G	T	-0.0325	0.0057	1.44901E-08	0.0076	0.0101	0.4499
rs7105860	11	27306364	C	G	-0.0468	0.0059	2.35885E-15	0.0165	0.0102	0.1056
rs71390846	16	86714715	C	G	-0.0484	0.0075	1.38099E-10	-0.0235	0.013	0.0696194
rs725670	11	121913230	A	G	-0.0322	0.0059	3.61202E-08	-0.0197	0.0106	0.0629898
rs73169678	7	150953205	A	C	0.0619	0.0091	1.05293E-11	-0.0014	0.0158	0.9283
rs73305797	7	30997087	T	A	-0.0422	0.0067	2.398E-10	0.0181	0.0118	0.1233
rs73349318	10	112245400	T	A	0.0472	0.0085	2.68201E-08	0.0006	0.0157	0.9702
rs73719807	7	121191251	C	A	0.0925	0.0112	1.14288E-16	0.007	0.0205	0.7329
rs74394007	3	156692207	C	A	-0.0608	0.0083	2.46093E-13	0.0061	0.0146	0.676
rs7548588	1	110475971	C	T	0.0367	0.0058	2.208E-10	0.0003	0.0101	0.9753
rs757138	7	27989403	G	T	0.0348	0.0063	3.33403E-08	-0.0041	0.0114	0.721601
rs7586085	2	166577489	G	A	-0.0532	0.0057	8.63575E-21	-0.0081	0.0099	0.4094
rs76051363	4	1006987	T	C	-0.0794	0.0085	1.38995E-20	-0.013	0.015	0.3863
rs7728694	5	88288341	T	G	-0.0503	0.0059	1.29599E-17	-0.0082	0.0103	0.4262
rs7740042	6	151971720	A	T	-0.0494	0.0071	2.70707E-12	-0.0205	0.0126	0.1026
rs7741085	6	44636919	T	C	0.0423	0.0057	1.50904E-13	0.003	0.0103	0.770699
rs78667121	13	43200103	A	G	0.1326	0.018	1.70098E-13	0.0027	0.0315	0.9319
rs8047501	16	392318	G	A	-0.0524	0.0059	1.13397E-18	0.0086	0.0104	0.4088

rs8070128	17	17804725	T	C	-0.0394	0.0059	1.98381E-11	-0.0163	0.0102	0.1088
rs818427	5	112221869	T	C	0.0342	0.0061	2.37197E-08	-0.0041	0.0105	0.6936
rs838721	2	234303405	G	A	0.0314	0.0057	4.48002E-08	-0.0025	0.0101	0.8065
rs884205	18	60054857	C	A	0.0531	0.0068	4.39036E-15	-0.0116	0.0119	0.3296
rs9594738	13	42952145	T	C	-0.0614	0.0057	3.84061E-27	-0.0017	0.01	0.8612
rs9910055	17	42283037	T	C	0.0442	0.0067	3.11889E-11	0.0032	0.0117	0.785899
rs9972944	17	63771079	G	A	-0.0363	0.0059	6.86594E-10	-0.005	0.0103	0.6269
rs9976876	21	36970350	T	G	-0.0375	0.0058	8.00571E-11	0.0161	0.01	0.106

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; BMD, bone mineral density.

Table 18 Mendelian Randomization estimates of CHD, HF and stroke on total body BMD

Exposure	Outcome	IV		Weighted median			MR-Egger			F-statistic		
		SNPs(N)	Beta	95% CI	P-value	Beta	95% CI	P-value	Beta		95% CI	P-value
	CHD	34	0.0651	-0.0606–0.1	0.310	0.039	-0.1255–0.	0.6410	0.16	-0.1499–0.	0.3110	71.4209
				907	1	17	2038		59	4816		
	Total body BMD											
	HF	68	-0.015	-0.0603–0.0	0.501	-0.02	-0.0920–0.	0.4322	-0.03	-0.1585–0.	0.5234	71.9453
				4	295	4	63	0394		91	0803	
	Stroke	80	0.0237	-0.0287–0.0	0.375	0.049	-0.0287–0.	0.3125	0.07	-0.0678–0.	0.3125	71.7089
				762	4	7	1280		30	2138		

Abbreviations: BMD, bone mineral density; CHD, coronary heart disease; HF, heart failure; IVW, inverse-variance weighted; CI, confidence interval; MR Mendelian randomization; IV:instrumental variable

Table19 Abnormal SNPs in MR-PRESSO analysis of total body BMD on HF

SNP	Chr	Pos	EA	OA	Total body BMD (Exposure)			HF (Outcome)		
					Beta	SE	P-value	Beta	SE	P-value
rs2873195	17	2064702	T	A	0.0406	0.0062	4.31122E-11	0.0377	0.0123	0.00226798

Abbreviations: SNP, single-nucleotide polymorphism; Chr, chromosome; Pos, position; EA, effect allele; OA, other allele; SE, standard error; HF, heart failure; BMD, bone mineral density.

CONTENTS OF FIGURES




FIGURE 1 Conceptual Framework of the Study Design. 'SNP' denotes Single Nucleotide Polymorphism, 'CHD' stands for coronary heart disease, 'HF' represents heart failure, 'BMD' refers to bone mineral density, and 'IVW' indicates inverse-variance weighted. The diagram is founded on three critical assumptions: (1) Instrumental variables exhibit a strong correlation with the intended risk factor; (2) Instrumental variables maintain independence from confounding factors; (3) Instrumental variables influence the outcome exclusively via the risk factor, not through secondary pathways. Sensitivity checks, including MR-PRESSO and the leave-one-out analysis, are illustrated as well.




Figure 2 Scatter plots of estimated effect sizes for exposure (coronary heart disease, heart failure, stroke) on outcome (total body bone mineral density). 'SNP' denotes Single Nucleotide Polymorphism.




Figure 3 Forest plots of estimated effect sizes for exposure (coronary heart disease, heart failure, stroke) on outcome (total body bone mineral density). 'MR' refers to Mendelian randomization.




Figure 4 The leave-one-out method for exposure (coronary heart disease, heart failure, stroke) on outcome (total body bone mineral density). 'MR' refers to Mendelian randomization.




Figure 5 Scatter plots of estimated effect sizes for exposure (total body bone mineral density) on outcome (coronary heart disease, heart failure, stroke). 'SNP' denotes Single Nucleotide Polymorphism.




Figure 6 Forest plots of estimated effect sizes for exposure (total body bone mineral density) on outcome (coronary heart disease, heart failure, stroke). 'MR' refers to Mendelian randomization.




Figure 7 The leave-one-out method for exposure (total body bone mineral density) on outcome (coronary heart disease, heart failure, stroke). 'MR' refers to Mendelian randomization.